N,N-Dimethyl-2-(3-fluorophenyl)ethylamine | 1067275-92-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N-Dimethyl-2-(3-fluorophenyl)ethylamine
• 英文别名: 2-(3-fluorophenyl)-N,N-dimethylethanamine
• CAS: 1067275-92-6
• 化学式: C₁₀H₁₄FN
• 分子量: 167.226
• InChiKey: ZXRFTQNOESGYCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 3-氟苯乙胺 在 甲酸 作用下， 以 水 为溶剂， 反应 16.0h， 生成 N,N-Dimethyl-2-(3-fluorophenyl)ethylamine
  参考文献：
  名称：

  Structure–activity correlations for β-phenethylamines at human trace amine receptor 1

  摘要：

  A cell line in which RD-HGA16 cells were stably transfected with the hTAAR 1 receptor was created and utilized to carry out a systematic evaluation of a series of beta-phenethylamines. Fair agreement was observed with data obtained for aryl and ethylene chain substituted analogs in an AV12-664 cell line in which hemagglutinin-tagged hTAAR 1 was stably co-expressed with rat Gas. Analogs with multiple substituents as well as analogs with bulky groups were found to be partial agonists. Analogs in which the primary amino group was converted to a secondary or a tertiary amino group by N-methylation were also partial agonists. Comparative Molecular Field Analysis (CoMFA) using the potency data yielded a regression coefficient r(2) of 0.824. The steric field contribution to the model was 61% with the balance (39%) contributed by the electrostatic field. The collective results suggest that increasing steric bulk both at the amino nitrogen, particularly by N-dimethylation, and at the 4-position of the aromatic ring leads to low efficacy ligands. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.06.009

文献信息

• 8-OXODIHYDROPURINE DERIVATIVE
  申请人：Aachi Keiji

  公开号：US20120172347A1

  公开（公告）日：2012-07-05

  The present invention provides a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof (wherein W represents a hydrogen atom, a halogen atom, or the others; A represents an alkyl group optionally substituted by aryl group or the others, an aryl group, or the others; and one of X and Y represents a di-substituted alkylaminocarbonyl group, or the others, and the other represents a hydrogen atom, an alkyl group, an alkylcarbonyl group, or the others); a medicament or a pharmaceutical composition for treatment or prophylaxis of FAAH-related diseases such as depression, anxiety disorder or pains, comprising the compound or the like as an active ingredient; a use of the compound or the like; and a method for treatment or prophylaxis using the compound or the like.

  本发明提供一种由式（1）表示的化合物或其药用可接受的盐（其中W代表氢原子、卤素原子或其他；A代表可选地被芳基取代的烷基基团或其他、芳基团或其他；X和Y中的一个代表二取代的烷基氨基羰基团或其他，另一个代表氢原子、烷基基团、烷基羰基团或其他）；一种治疗或预防FAAH相关疾病如抑郁症、焦虑症或疼痛的药物或药物组合物，包括该化合物或类似物作为活性成分；一种使用该化合物或类似物的用途；以及使用该化合物或类似物的治疗或预防方法。
• Mammalian and Bacterial Nitric Oxide Synthase Inhibitors
  申请人：Northwestern University

  公开号：US20160122302A1

  公开（公告）日：2016-05-05

  Compounds and related methods for inhibition of mammalian and bacterial nitric oxide synthase.

  化合物及相关方法，用于抑制哺乳动物和细菌的一氧化氮合酶。
• METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF
  申请人：Englert Ullrich

  公开号：US20100267977A1

  公开（公告）日：2010-10-21

  The present invention relates to a process for preparing cycloplatinated platinum(II) complexes, platinum(II) complexes prepared by this process and the use thereof for the treatment of tumor diseases and/or hemo blastoses.
• US8394979B2
  申请人：——

  公开号：US8394979B2

  公开（公告）日：2013-03-12
• US8735406B2
  申请人：——

  公开号：US8735406B2

  公开（公告）日：2014-05-27